Objective: The aim of the present study is to evaluate the plasma total cell-free DNA and cell-free fetal DNA level in maternal venous samples obtained from pre-eclamptic pregnant women during the third trimester (gestational age>28 weeks) and whether it shows a correlation with uteroplacental blood flow.
Materials and methods: This was a case–control study in which plasma total cell-free DNA, cell-free fetal DNA levels, and uteroplacental blood flow including umbilical artery resistance index, uterine artery resistance index and pulsitility index, and middle cerebral artery/umbilical artery pulsitility index were measured in 60 women diagnosed with pre-eclampsia, representing the study group, and another 60 normotensives were taken as controls. Both total cell-free DNA and cell-free fetal DNA were quantified by real-time PCR using the RASSF1A gene before and after treatment by methylation-sensitive restriction enzyme, respectively, irrespective of the sex of the fetus.
Results: Our results showed that there was a positive correlation between plasma cell-free fetal DNA, total cell-free DNA, and uteroplacental blood flow in pre-eclamptic women (P<0.05). To detect pre-eclampsia, the best cut-off value for plasma cell-free fetal DNA level was 80 copies/ml and that for plasma total cell-free DNA level was 137 copies/ml.
Conclusion: Our results found that there was a positive correlation between plasma cell-free fetal DNA level and the severity of pre-eclampsia. In addition, we found a correlation between plasma cell-free fetal, total cell-free DNA level, and uteroplacental blood flow in pre-eclamptic women during the third trimester.
aDepartment of Reproductive Health and Family Planning Research, National Research Centre, Giza
bDepartment of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt
Correspondence to Wael El-Garf, MD, Department of Reproductive Health and Family Planning Research, Medical Research Division, National Research Centre, Elbohouth Street, Dokki, 12311 Giza, Egypt Tel: +2 01001987651; fax: +202 37601877; e-mail: firstname.lastname@example.org
Received March 11, 2013
Accepted May 5, 2013